Clinical trials: Pediatric ADHD
Mood Disorder
Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder
This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability…
- Trial name
- NCT00025935
- Testing
- Lithium
- Where
- United States
- Volunteers
- 2,350 people
- Sponsor
- National Institute of Mental Health (NIMH)
ADHD
tRNS Treatment for ADHD Symptoms
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD.
- Trial name
- NCT06189703
- Testing
- tRNS
- Where
- 5 sites in United States, Israel
- Volunteers
- 146 people
- Sponsor
- Innosphere
Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder
A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter bridging clinical trial designed to evaluate the efficacy and safety of viloxazine extended-release capsules (AK-D101) compared with placebo in Korean…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder, ADHD
- Trial name
- AK-D101_BS (NCT07678827)
- Testing
- AK-D101
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Alvogen Korea
Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder
Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)
This research study is carried out to examine the effects of Phosphatidylserine-Omega 3 supplements (i.e., Vayarin) among children with Autism Spectrum Disorder (ASD) and ADHD.
- Trial name
- NCT03115671
- Testing
- Vayarin
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- Institute of Mental Health, Singapore
Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder
Characterization and Brain Mechanisms of Frustration in Youth With Severe Irritability or Attention Deficit Hyperactivity Disorder (ADHD)
Background: Irritability is an elevated proneness to anger. Children with irritability have difficulty tolerating frustration. They get angry and have temper outbursts more easily than their others their age.
- Conditions
- Disruptive Mood Dysregulation Disorder, Attention Deficit Hyperactivity Disorder, Normal Physiology
- Trial name
- NCT05357495
- Testing
- Affective Posner fMRI frustration induction task
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
ADHD, ADD
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
- Trial name
- NCT00301236
- Testing
- Dexmethylphenidate HCl extended-release capsules
- Where
- 25 sites in United States
- Volunteers
- 252 people
- Sponsor
- Novartis
Pediatric Attention Deficit Hyperactivity Disorder
Dasotraline SEP360-105 Pediatric PK/PD Study
Pediatric PK study of SEP-225289 (Dasotraline)
- Trial name
- NCT02195167
- Testing
- Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention-Deficit Hyperactivity Disorder
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
The main purpose of this study is to determine the rate and extent of absorption of one or more modified release formulations of amphetamine (HLD100) in both adolescents and children with ADHD.
- Trial name
- NCT01886469
- Testing
- HLD100-B, HLD100-C, HLD100-E
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia
There has been an increased interest in the association between ADHD and sleep disorders over the past years. A high incidence of sleep disturbance, ranging from 10% to 70%, has been identified in ADHD children regardless of…
- Trial name
- Zolkids (NCT00318448)
- Testing
- Zolpidem (SL800750)
- Where
- 2 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- Sanofi
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890240
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Attention Deficit Hyperactivity Disorder
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
This study is a single arm, open-label, pilot study to assess midline frontal theta (MFT) power as measured by stimulus-locked electroencephalogram (EEG) before and after treatment with AKL-T01 for improving attention in…
- Trial name
- NCT03844269
- Testing
- AKL-T01
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD
The purpose of the study is to compare atomoxetine hydrochloride and methylphenidate hydrochloride in pediatric patients with ADHD.
- Trial name
- NCT00486083
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- 3 sites in China, Mexico and 1 more
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD
Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.
- Trial name
- NCT00444574
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 282 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
- Trial name
- NCT00151970
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 128 people
- Sponsor
- Noven Therapeutics
Disruptive Behavior
Clinical and Social Trajectory of Children and Adolescents With Disruptive Behavior
Conduct disorders are defined as "repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate norms are violated".
- Trial name
- TRAJECTORY (NCT02828969)
- Testing
- Phone call or physical consultation
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Pediatric Onset Multiple Sclerosis, ADHD Predominantly Inattentive Type
Cognitive Impairment in Pediatric Onset Multiple Sclerosis
Computer-assisted rehabilitation of attention deficits in pediatric Multiple Sclerosis and ADHD patients recruited during the study "Cognitive impairment in Pediatric Onset Multiple Sclerosis: research of biomarkers predictive of…
- Trial name
- NCT03190902
- Testing
- Attention Processing Training program (APT), nonspecific computer training (n-ST)
- Volunteers
- 36 people
- Sponsor
- Pietro Iaffaldano
Attention Deficit Disorder, Attention Deficit Disorder (ADD)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the…
- Conditions
- Attention Deficit Disorder, Attention Deficit Disorder (ADD), Attention Deficit Disorder with Hyperactivity, ADHD
- Trial name
- NOVA (NCT06797570)
- Testing
- Communication Strategy for Side Effect Counseling in ADHD Treatment
- Volunteers
- 130 people
- Sponsor
- St. Antonius Hospital
Epilepsy Intractable
Pediatric Epilepsy
The purpose of the research is to better understand how the human brain accomplishes the basic cognitive tasks of learning new information, recalling stored information, making decisions or choices about presented information and…
- Trial name
- NCT07350551
- Testing
- Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (process by which JNJ-31001074 is absorbed, distributed, metabolized, and eliminated by the body) after a single dose of JNJ-31001074.
- Trial name
- NCT00890292
- Testing
- JNJ-31001074
- Volunteers
- 18 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.